# Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Source: https://onco.cc/trials/nct04963595/  
OnCo record `nct04963595` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pyrotinib, Vinorelbine and Inetetamab in Breast cancer, run by Zhiyong Yu, with a status the registry has not verified recently.

## Summary

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer is a phase 2 interventional study registered as NCT04963595 by Zhiyong Yu, with 100 participants planned, started 2021-08-01 and due to reach its primary completion in 2023-01-31. Interventions recorded: Pyrotinib, Vinorelbine, Inetetamab. Conditions recorded: Metastatic Breast Cancer.

Linked to the drug Inetetamab because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04963595
- Phase: 2
- Setting: Phase II Study of Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
- Sponsor: Zhiyong Yu
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT04963595: https://clinicaltrials.gov/study/NCT04963595

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Inetetamab](https://onco.cc/drugs/inetetamab/), [Pyrotinib](https://onco.cc/drugs/pyrotinib/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)

---
JSON: https://onco.cc/api/v1/entities/nct04963595.json